| scholarly article | Q13442814 |
| P50 | author | Josep Dalmau | Q37828790 |
| P2093 | author name string | Karen F Berman | |
| Joseph C Masdeu | |||
| P2860 | cites work | Abnormal prefrontal activation directly related to pre-synaptic striatal dopamine dysfunction in people at clinical high risk for psychosis | Q48394255 |
| ABC Schizophrenia study: an overview of results since 1996. | Q48478322 | ||
| Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis | Q48545839 | ||
| Antibodies to surface dopamine-2 receptor and N-methyl-D-aspartate receptor in the first episode of acute psychosis in children | Q48578056 | ||
| N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels | Q48611711 | ||
| Anti-N-methyl-D-aspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder in an adolescent | Q48715569 | ||
| Seroprevalence of autoantibodies against brain antigens in health and disease | Q48774317 | ||
| Anti-NMDA receptor encephalitis: an important differential diagnosis in psychosis | Q48853803 | ||
| Clinical specificities of adult male patients with NMDA receptor antibodies encephalitis. | Q50664714 | ||
| Brain immunohistopathological study in a patient with anti-NMDAR encephalitis | Q59697804 | ||
| N-Methyl-D-Aspartate Receptor Autoantibodies in Psychiatric Illness | Q60459490 | ||
| Epidemiology of early-onset schizophrenia | Q72009122 | ||
| Lack of anti-NMDA receptor autoantibodies in the serum of subjects with schizophrenia | Q83323658 | ||
| Autoimmune encephalopathies | Q85235564 | ||
| Altered neuregulin 1-erbB4 signaling contributes to NMDA receptor hypofunction in schizophrenia | Q24293245 | ||
| Biological insights from 108 schizophrenia-associated genetic loci | Q24561833 | ||
| Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis | Q24614608 | ||
| Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis | Q24620536 | ||
| The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project | Q24621267 | ||
| Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study | Q24627766 | ||
| Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies | Q24642126 | ||
| Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophrenia | Q24646206 | ||
| Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma | Q24653500 | ||
| Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment | Q26781620 | ||
| Contribution of NMDA receptors to dorsolateral prefrontal cortical networks in primates | Q26820417 | ||
| Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment | Q26852047 | ||
| Translating the MAM model of psychosis to humans | Q26860217 | ||
| The role of glutamatergic inputs onto parvalbumin-positive interneurons: relevance for schizophrenia | Q27023087 | ||
| Structural and functional features of central nervous system lymphatic vessels | Q27316769 | ||
| Crystal structure of a heterotetrameric NMDA receptor ion channel | Q27684006 | ||
| Whole-brain mapping of direct inputs to midbrain dopamine neurons | Q44901176 | ||
| Early recognition of anti-N-methyl D-aspartate (NMDA) receptor encephalitis presenting as acute psychosis | Q45348653 | ||
| First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients | Q46724711 | ||
| Psychotic syndrome associated with anti-Ca/ARHGAP26 and voltage-gated potassium channel antibodies | Q47661365 | ||
| Spike timing-dependent plasticity at GABAergic synapses in the ventral tegmental area. | Q47906113 | ||
| Evidence for a Specific Integrative Mechanism for Episodic Memory Mediated by AMPA/kainate Receptors in a Circuit Involving Medial Prefrontal Cortex and Hippocampal CA3 Region | Q48141932 | ||
| Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis | Q48166222 | ||
| Absence of N-Methyl-D-Aspartate Receptor IgG Autoantibodies in Schizophrenia: The Importance of Cross-Validation Studies | Q48180031 | ||
| Topographical organization of GABAergic neurons within the ventral tegmental area of the rat. | Q48363521 | ||
| NMDA receptor structures reveal subunit arrangement and pore architecture | Q27684638 | ||
| Potassium channel antibodies in two patients with reversible limbic encephalitis | Q28206692 | ||
| Defining criteria for autoimmune diseases (Witebsky's postulates revisited) | Q28255257 | ||
| Glutamate receptor ion channels: structure, regulation, and function | Q28290774 | ||
| Disease-relevant autoantibodies in first episode schizophrenia | Q28296584 | ||
| Prevalence of anti-N-methyl-D-aspartate (NMDA) receptor [corrected] antibodies in patients with schizophrenia and related psychoses: a systematic review and meta-analysis | Q28303840 | ||
| Mice with reduced NMDA receptor expression display behaviors related to schizophrenia | Q28510751 | ||
| Cortical inhibitory neurons and schizophrenia | Q29547683 | ||
| NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders | Q29617936 | ||
| Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 | ||
| Recent advances in the phencyclidine model of schizophrenia | Q29618917 | ||
| Neurophysiological models for new treatment development in schizophrenia: early sensory approaches. | Q30384452 | ||
| Pyramidal cell selective ablation of N-methyl-D-aspartate receptor 1 causes increase in cellular and network excitability | Q30388341 | ||
| Autoimmune encephalopathies | Q30389491 | ||
| Sensory processing dysfunction in the personal experience and neuronal machinery of schizophrenia | Q30394589 | ||
| Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features | Q30463819 | ||
| Neuropsychiatric autoimmune encephalitis without VGKC-complex, NMDAR, and GAD autoantibodies: case report and literature review | Q30608556 | ||
| Imaging glutamate in schizophrenia: review of findings and implications for drug discovery | Q30685335 | ||
| Inflammation-related genes up-regulated in schizophrenia brains | Q33297810 | ||
| Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study | Q33551430 | ||
| Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor | Q33601343 | ||
| Catechol-o-methyltransferase valine(158)methionine genotype and resting regional cerebral blood flow in medication-free patients with schizophrenia | Q33615547 | ||
| N-methyl-D-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes | Q33882739 | ||
| Serum IgG antibodies against the NR1 subunit of the NMDA receptor not detected in schizophrenia. | Q33956303 | ||
| Reduced prefrontal activity predicts exaggerated striatal dopaminergic function in schizophrenia | Q33957624 | ||
| Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study | Q34144095 | ||
| Retrospective analysis of NMDA receptor antibodies in encephalitis of unknown origin. | Q34148772 | ||
| Mouse models of genetic effects on cognition: relevance to schizophrenia | Q34183979 | ||
| NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons | Q34197064 | ||
| Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome | Q34225761 | ||
| Molecular evidence of N-methyl-D-aspartate receptor hypofunction in schizophrenia. | Q34306261 | ||
| Increased prevalence of diverse N-methyl-D-aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate glutamate receptor encepha | Q34323973 | ||
| Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. | Q34399975 | ||
| Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia | Q34507860 | ||
| De novo mutations in schizophrenia implicate synaptic networks | Q34540372 | ||
| From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment | Q34632695 | ||
| NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease | Q34651972 | ||
| Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice | Q34842262 | ||
| AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. | Q34972785 | ||
| Acute mechanisms underlying antibody effects in anti-N-methyl-D-aspartate receptor encephalitis | Q34975413 | ||
| Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. | Q35144356 | ||
| Molecular pharmacology of human NMDA receptors | Q35911379 | ||
| Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. | Q36005655 | ||
| Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. | Q36197690 | ||
| NMDA receptor function in large-scale anticorrelated neural systems with implications for cognition and schizophrenia | Q36339850 | ||
| Rationale for a trial of immunosuppressive therapy in acute schizophrenia | Q36716413 | ||
| Microglial Activity in People at Ultra High Risk of Psychosis and in Schizophrenia: An [(11)C]PBR28 PET Brain Imaging Study. | Q36766806 | ||
| Neuronal autoantigens--pathogenesis, associated disorders and antibody testing | Q37032830 | ||
| Frequency and characteristics of isolated psychiatric episodes in anti–N-methyl-d-aspartate receptor encephalitis | Q37258132 | ||
| Central auditory dysfunction in schizophrenia as revealed by the mismatch negativity (MMN) and its magnetic equivalent MMNm: a review | Q37260696 | ||
| Schizophrenia, "just the facts" 4. Clinical features and conceptualization | Q37425853 | ||
| The involvement of the NMDA receptor D-serine/glycine site in the pathophysiology and treatment of schizophrenia | Q37583070 | ||
| A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia | Q37765676 | ||
| GluN3 subunit-containing NMDA receptors: not just one-trick ponies | Q37975344 | ||
| The anatomical and cellular basis of immune surveillance in the central nervous system. | Q38035711 | ||
| Influence of GluN2 subunit identity on NMDA receptor function. | Q38078685 | ||
| Distinct functional and pharmacological properties of Triheteromeric GluN1/GluN2A/GluN2B NMDA receptors. | Q38316913 | ||
| Clinical Spectrum of Encephalitis Associated With Antibodies Against the α-Amino-3-Hydroxy-5-Methyl-4-Isoxazolepropionic Acid Receptor: Case Series and Review of the Literature | Q38568146 | ||
| Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey | Q39435279 | ||
| Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders | Q39535640 | ||
| Schizophrenia susceptibility pathway neuregulin 1-ErbB4 suppresses Src upregulation of NMDA receptors. | Q40613981 | ||
| Synaptic dysregulation in a human iPS cell model of mental disorders | Q41534293 | ||
| Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity | Q42272536 | ||
| Src kinase as a mediator of convergent molecular abnormalities leading to NMDAR hypoactivity in schizophrenia. | Q42352815 | ||
| Increased synaptic dopamine function in associative regions of the striatum in schizophrenia | Q43145582 | ||
| NMDA receptors subserve persistent neuronal firing during working memory in dorsolateral prefrontal cortex | Q43238242 | ||
| Increased inflammatory markers identified in the dorsolateral prefrontal cortex of individuals with schizophrenia | Q43444866 | ||
| Clinical relevance of serum antibodies to extracellular N-methyl-D-aspartate receptor epitopes | Q43511105 | ||
| Asymmetrical reductions of hippocampal NMDAR1 glutamate receptor mRNA in the psychoses. | Q43757912 | ||
| Association of common copy number variants at the glutathione S-transferase genes and rare novel genomic changes with schizophrenia | Q43801006 | ||
| P433 | issue | 5 | |
| P921 | main subject | autoantibody | Q785022 |
| psychosis | Q170082 | ||
| P304 | page(s) | 300-310 | |
| P577 | publication date | 2016-04-26 | |
| P1433 | published in | Trends in Neurosciences | Q3538443 |
| P1476 | title | NMDA Receptor Internalization by Autoantibodies: A Reversible Mechanism Underlying Psychosis? | |
| P478 | volume | 39 |
| Q92046168 | An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models |
| Q64086865 | Anti-NMDA Receptor Autoantibody Is an Independent Predictor of Hospital Mortality but Not Brain Dysfunction in Septic Patients |
| Q42335282 | Anti-NMDAR antibodies as a new piece in schizophrenia's puzzle |
| Q39094833 | Anti-phospholipid syndrome associated with schizophrenia description of five patients and review of the literature |
| Q89659044 | Astroglial Connexin 43 Deficiency Protects against LPS-Induced Neuroinflammation: A TSPO Brain µPET Study with [18F]FEPPA |
| Q39180685 | Autoantibodies to Synaptic Receptors and Neuronal Cell Surface Proteins in Autoimmune Diseases of the Central Nervous System |
| Q91025656 | Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin |
| Q50203826 | Can functional connectivity diagnose autoantibody-associated encephalitides? |
| Q47649952 | Developmental Differences Between Schizophrenia and Bipolar Disorder |
| Q47899912 | Effects of selective calcium-permeable AMPA receptor blockade by IEM 1460 on psychotomimetic-induced hyperactivity in the mouse |
| Q37627540 | Efficacy of Memantine in Schizophrenic Patients: A Systematic Review. |
| Q95324894 | Evidence-based umbrella review of 162 peripheral biomarkers for major mental disorders |
| Q48423961 | In vitro effects of a human monoclonal antibody against the N-methyl-d-aspartate receptor |
| Q55511188 | Membrane-bound and soluble forms of an NMDA receptor extracellular domain retain epitopes targeted in auto-immune encephalitis. |
| Q39030050 | NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: The 2016 Cotzias Lecture |
| Q47120197 | NMDAR encephalitis: passive transfer from man to mouse by a recombinant antibody |
| Q37643885 | Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in Psychiatric Patients |
| Q98725910 | Reduced serial dependence suggests deficits in synaptic potentiation in anti-NMDAR encephalitis and schizophrenia |
| Q30355619 | Spatial and temporal boundaries of NMDA receptor hypofunction leading to schizophrenia. |
| Q46001292 | Superficial white matter damage in anti-NMDA receptor encephalitis. |
| Q52559050 | The Emerging Immunogenetic Architecture of Schizophrenia. |
| Q55413861 | The prevalence and treatment outcomes of antineuronal antibody-positive patients admitted with first episode of psychosis. |
Search more.